Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
P07451

UPID:
CAH3_HUMAN

ALTERNATIVE NAMES:
Carbonate dehydratase III; Carbonic anhydrase III

ALTERNATIVE UPACC:
P07451; B2R867; B3KUC8; O60842

BACKGROUND:
The enzyme Carbonic anhydrase 3, known alternatively as Carbonate dehydratase III or Carbonic anhydrase III, is essential for the reversible hydration of carbon dioxide. This process is vital for maintaining acid-base balance and CO2 transport across tissues. Carbonic anhydrase 3's activity is integral to various physiological processes, highlighting its importance in metabolic and respiratory health.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of Carbonic anhydrase 3 offers a pathway to innovative therapeutic approaches. Given its central role in acid-base equilibrium and CO2 management, targeting this enzyme could yield novel treatments for metabolic and respiratory disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.